Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said